MX2020009288A - Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas. - Google Patents

Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas.

Info

Publication number
MX2020009288A
MX2020009288A MX2020009288A MX2020009288A MX2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A
Authority
MX
Mexico
Prior art keywords
isoindoline
isoindole
dione
compositions
methods
Prior art date
Application number
MX2020009288A
Other languages
English (en)
Spanish (es)
Inventor
William R Baker
Original Assignee
Amgen Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Europe Gmbh filed Critical Amgen Europe Gmbh
Publication of MX2020009288A publication Critical patent/MX2020009288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MX2020009288A 2018-03-07 2019-03-06 Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas. MX2020009288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07
PCT/EP2019/055576 WO2019170750A1 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2020009288A true MX2020009288A (es) 2020-09-28

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009288A MX2020009288A (es) 2018-03-07 2019-03-06 Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas.

Country Status (11)

Country Link
US (1) US11639332B2 (cg-RX-API-DMAC10.html)
EP (1) EP3762365B1 (cg-RX-API-DMAC10.html)
JP (1) JP7396991B2 (cg-RX-API-DMAC10.html)
AR (1) AR114666A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019229583B2 (cg-RX-API-DMAC10.html)
CA (1) CA3093196A1 (cg-RX-API-DMAC10.html)
ES (1) ES2987705T3 (cg-RX-API-DMAC10.html)
MA (1) MA52266A (cg-RX-API-DMAC10.html)
MX (1) MX2020009288A (cg-RX-API-DMAC10.html)
TW (1) TW202000646A (cg-RX-API-DMAC10.html)
WO (1) WO2019170750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
KR20030026936A (ko) * 2000-06-29 2003-04-03 니폰 가야꾸 가부시끼가이샤 색소증감 광전 변환소자
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas

Also Published As

Publication number Publication date
ES2987705T3 (es) 2024-11-15
JP7396991B2 (ja) 2023-12-12
JP2021517134A (ja) 2021-07-15
AR114666A1 (es) 2020-09-30
EP3762365B1 (en) 2024-02-21
AU2019229583B2 (en) 2024-06-13
US11639332B2 (en) 2023-05-02
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
TW202000646A (zh) 2020-01-01
US20200392082A1 (en) 2020-12-17
CA3093196A1 (en) 2019-09-12
EP3762365A1 (en) 2021-01-13
WO2019170750A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
CL2020002919A1 (es) Inhibidores de mcl-1
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2017001124A1 (es) Agentes inmunomoduladores
ECSP19045511A (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
MX2016016993A (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo.
AR104387A1 (es) Composiciones detergentes
CL2021002847A1 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
CL2018000927A1 (es) Terapia combinada para el tratamiento de neoplasias malignas
NZ714662A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
UY34893A (es) Derivados de azaindol
PY2039449A (es) Inhibidortes tricíclicos de kars dependientes de akr1c3
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX2021000154A (es) Metodos de tratamiento de fibrosis hepatica que usan inhibidores de calpaina.
MX2021007899A (es) Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.
BR112022000325A2 (pt) Indazois e azaindazois como inibidores de lrrk2
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
MX2018008732A (es) Inhibicion de la reaccion alergica usando un inhibidor de il-33.
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
MX2018007964A (es) Metodos de uso de inhibidores de caspasas en el tratamiento de la enfermedad hepatica.
AR104353A1 (es) Proceso para entrecruzar polipropileno, producto resultante y proceso para reciclarlo
MX2019002259A (es) Inhibicion de la actividad de la olig2.